BioCentury | Jan 23, 2020
Product Development

Thirteen years from founding, Epizyme scores first FDA approval

Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang its hat and foundational hypothesis. On Thursday, its Tazverik tazemetostat became the first approved therapy to treat epithelioid sarcoma....
BC Extra | May 30, 2019
Company News

Epizyme looks to sarcoma for first approval

More than a decade after it was founded and after nearly $1 billion raised, Epizyme has submitted its first NDA to FDA for a small molecule inhibitor of an epigenetic cancer target. The company is...
BC Innovations | May 23, 2018
Distillery Therapeutics


INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BC Extra | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BC Innovations | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BC Innovations | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BC Innovations | Jun 27, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting SIRT1 could help treat osteoarthritis. In cartilage samples from patients, levels of activated DOT1L , a negative regulator of SIRT1, were lower than in samples from non-arthritic...
BC Week In Review | Nov 10, 2016
Company News

Epizyme, NCI deal

Epizyme entered into two cooperative research and development agreements (CRADAs) with NCI's Cancer Therapy Evaluation Program (CTEP) to evaluate tazemetostat and pinometostat from Epizyme to treat cancer. NCI will manage and fund the studies, which...
BC Innovations | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Histone methyltransferase DOT1L (DOT1L); bromodomain containing 4 (BRD4)

Cancer INDICATION: Leukemia Cell culture studies suggest combining inhibitors of DOT1L and BRD4 could help treat mixed lineage leukemia (MLL). In mouse hematopoietic cells transformed by a chimeric version of the MLL-ENL fusion oncogene , a...
Items per page:
1 - 10 of 61